Hemorio

Running trials

• Recruiting

  A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

  NCT06379789· Phase 1/2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

  NCT05431088· Phase 2/3· Pfizer· Source

• Active, not recruiting

  Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

  NCT04994717· Phase 3· Amgen· Source

• Recruiting

  International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

  NCT00358943· Genzyme, a Sanofi Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gaucher disease1 recruiting
• Haemophilia1 recruiting
• Sickle cell disease1 recruiting

Closed trials

• Terminated

  A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

  NCT05348915· Phase 3· Pfizer· Source

• Completed

  A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

  NCT05147662· Phase 3· Bayer· Source

• Completed

  Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients

  NCT05255445· Westat· Source

• Completed

  A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

  NCT05075824· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

  NCT04935879· Phase 3· Pfizer· Source

• Completed

  Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

  NCT04562766· Phase 3· Principia Biopharma, a Sanofi Company· Source

• Completed

  Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

  NCT04084080· Phase 3· University of Pittsburgh· Source

• Completed

  A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

  NCT03587116· Phase 3· Pfizer· Source

• Completed

  ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)

  NCT02078427· Baxalta now part of Shire· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Sickle cell disease15 works · 6 trials